The facts
The substances listed are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. [1]
The document says compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. [1]
Listed conditions include a patient-specific prescription, registered ingredient manufacturers, identity and purity testing, single-active-ingredient products and reporting serious adverse events and quality problems. [1]
The public-inspection notice was filed on 28 October and is scheduled for Federal Register publication on 30 October. It invites comments for two weeks after publication and calls the draft nonbinding. [2]
Ars Technica separately reported the release of the policy and the accompanying HHS explanation on 28 October. [3]
Still unconfirmed
- The exact implementation timing, final policy text and interaction with state pharmacy regulation remain unresolved in the checked records. This release does not establish that the listed drugs are safe or effective.
Sources
References support the numbered facts above. Source checks: 29 Oct 2026, 03:26 UTC.
- 503A peptide enforcement-discretion policy and appendices
US Department of Health and Human Services · Primary source · 28 Oct 2026
Original 16-page document; policy conditions and Appendix A checked. No medical-benefit claims in its technical appendices are treated as established clinical results.
- Public-inspection notice 2026-22192
US Federal Register / Department of Health and Human Services · Primary source · 28 Oct 2026
Three-page notice explicitly describes a draft, says it is nonbinding and specifies the comment window. Scheduled 30 October publication is distinguished from the 28 October filing.
- Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA
Ars Technica · Reporting · 28 Oct 2026
Condé Nast health reporting, independently owned from HHS. The primary notice’s draft status takes precedence over the report’s description of a passed rule.